Table 5.
List of protein targets and potential drugs in targeted therapies of OS, based on [173].
| Protein | Potential Drug |
|---|---|
| DNMT1 (DNA (cytosine-5)-methyltransferase 1) | azacytidine (Vidaza), decitabine (Dacogen) |
| ERBB2 (receptor tyrosine–protein kinase erbB-2) | trastuzumab (Herceptin), lapatinib (Tycerb), afatinib (GIOTRIF/GILOTRIF), pertuzumab (PERJETA) |
| GSR (mitochondrial glutathione reductase | carmustine (GLIADEL® WAFER) |
| HDAC1 (histone deacetylase 1) | vorinostat (Zolinza) |
| HDAC2 (histone deacetylase 2) | romidepsin (Istodax) |
| KIT (mast/stem cell growth factor receptor kit) | imatinib (Gleevec), sorafenib (Nexavar), sunitinib (Sutent), pazopanib (Votrient), dasatinib (Sprycel), axitinib (Inlyta), nilotinib (Tasigna) |
| FGFR1 (fibroblast growth factor receptor 1) | lenvatinib (Lenvima) |
| MET (hepatocyte growth factor receptor) | cabozantinib (COMETRIQ), crizotinib (XALKORI) |
| MTOR (serine/threonine protein kinase mTOR) | temsirolimus (Torisel), everolimus (Afinitor) |
| PARP1 (poly (ADP–ribose) polymerase 1) | olaparib (AZD2281) |
| PDGFR α (platelet-derived growth factor receptor alpha) | imatinib (Gleevec), sorafenib (Nexavar), sunitinib (Sutent), pazopanib (Votrient), nilotinib (Tasigna), axitinib (Inlyta) and dasatinib (Sprycel) |
| PSMC2 (26S protease regulators subunit 7) | bortezomib (Velcade) |